1. Pink Sheet
  2. >>Geography
  3. >>Europe

Viebacher: Drug R&D Future Is In Collaboration, But Safe Harbors Needed

 
• By Faraz Kermani

Sanofi CEO says firms and other healthcare stakeholders all need to work together, but “no good deed goes unpunished.”

Without new models for pharmaceutical innovation based on translational and open research, the drug industry in Europe will stagnate and lose its competitive edge, according to Sanofi CEO Christopher Viehbacher. But that crucial collaboration between manufacturers could fall foul of antitrust laws unless safe harbors are created for that purpose, he argues.

Speaking at Biovision 2014 in Lyon, France on June 5, Viebacher said that manufacturers are continuing to transform the way...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

UK Looks To Auto-Match NHS Patients With Clinical Trials To Boost Recruitment

 
• By Vibha Sharma

The UK government is making it easier for millions of people to participate in clinical trials and is boosting transparency around how studies are delivered across the National Health Service.

UK’s Decentralized Manufacturing Rules Designed To Allow For ‘Future Developments’

 
• By Eliza Slawther

The UK drug regulator acknowledges that technology will “move on” and, as such, has designed its decentralized manufacturing regulation to be as “enduring” as possible. Experts from the MHRA explain what products are covered by the new framework and how it has been future-proofed.

More from Geography